With Janssen, Evotec also announced the licensing of a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. The agreement between Evotec and Janssen triggered an upfront payment of $ 8 m. Upon achievement of certain pre-clinical, clinical, regulatory and commercial goals, Evotec could receive milestone payments of up to $ 300 m per product. In addition, Janssen will pay royalties on future sales of any products that result from this collaboration.Evotec achieved key milestones within its product development alliance with MedImmune in the field of beta cell regeneration and received two milestone payments totalling € 1 m. EVT770 is currently in pre-clinical development and could enter trials within 24 months.
Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts